跳到正文
Cell Reports Medicine· Rachubinski·收录于· 16 小时前

A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome

A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome

来源:Cell Reports Medicine · doi.org